Grailhe P, Boyer-Neumann C, Haverkate F, Grimbergen J, Larrieu M J, Anglés-Cano E
Unité 143, Institut National de la Santé et de la Recherche Médicale, Centre Hospitalo-Universitaire de Bicêtre, France.
Blood Coagul Fibrinolysis. 1993 Oct;4(5):679-87.
The aim of this study was to investigate the interactions of t-PA and plasminogen with fibrin derived from an abnormal fibrinogen detected in a 40-year-old male patient who had had an episode of thrombophlebitis with pulmonary embolism. An abnormal fibrinogen was diagnosed on the basis of prolonged thrombin and reptilase times also detected in two other family members. Fibrinogen purified from plasma, in the presence of protease inhibitors, by glycine precipitations, gel filtration and affinity chromatography, was devoid of plasminogen, fibronectin, and vWf. SDS-PAGE analysis according to Laemmli under reducing conditions, showed an abnormal gamma chain (approximately 50% of the total) migrating in a more anodic position (M(r) 48 kDa). By PCR amplification and DNA sequencing, the abnormality was identified as an Asn308-->Lys mutation of the gamma chain. Since such a mutation constitutes a new plasmin cleavage site as first reported for fibrinogen Kyoto I, it may modify interactions of plasminogen and t-PA with carboxy-terminal lysine residues. Ligand-binding studies were therefore performed using intact and plasmin-degraded fibrin surfaces obtained from the abnormal fibrinogen. The plasminogen and t-PA binding isotherms obtained with the abnormal fibrinogen were similar to the control. Moreover, the stimulation by fibrin of plasminogen activation by t-PA was not different from the control. These results suggest (i) that the lysine 308 residue may not be exposed to plasmin cleavage in fibrin, and (ii) that the thrombotic accident of the propositus cannot be explained by an abnormality of the plasminogen/t-PA binding to fibrin.
本研究的目的是调查组织型纤溶酶原激活物(t-PA)和纤溶酶原与一名40岁男性患者体内检测到的异常纤维蛋白原所衍生的纤维蛋白之间的相互作用。该男性患者曾发生血栓性静脉炎并伴有肺栓塞。根据另外两名家庭成员中也检测到的凝血酶和蛇毒凝血酶时间延长,诊断出存在异常纤维蛋白原。通过在蛋白酶抑制剂存在的情况下,采用甘氨酸沉淀、凝胶过滤和亲和层析从血浆中纯化得到的纤维蛋白原,不含纤溶酶原、纤连蛋白和血管性血友病因子(vWf)。在还原条件下按照Laemmli方法进行的SDS-PAGE分析显示,一条异常的γ链(约占总量的50%)迁移至更阳极的位置(相对分子质量48 kDa)。通过PCR扩增和DNA测序,确定该异常为γ链的Asn308→Lys突变。由于这种突变构成了一个新的纤溶酶裂解位点,这是首次针对京都I型纤维蛋白原报道的,它可能会改变纤溶酶原和t-PA与羧基末端赖氨酸残基的相互作用。因此,使用从异常纤维蛋白原获得的完整和经纤溶酶降解的纤维蛋白表面进行了配体结合研究。用异常纤维蛋白原获得的纤溶酶原和t-PA结合等温线与对照相似。此外,纤维蛋白对t-PA激活纤溶酶原的刺激作用与对照无异。这些结果表明:(i)赖氨酸308残基在纤维蛋白中可能未暴露于纤溶酶裂解;(ii)先证者的血栓形成事件不能用纤溶酶原/t-PA与纤维蛋白结合异常来解释。